Jamaica: the Socially Responsible Investment Solution
24.11.2022 19:25:00 EET | Business Wire | Press release
As efforts intensify to attract international investors to Jamaica’s shores, the Jamaican Government has redoubled its efforts to attract more Local and Foreign Direct Investments.
The upcoming two-day ‘Invest Jamaica – the Nearshore Delivery Hub of the Caribbean’ conference, set to be held in Montego Bay on 29-30 November, will continue to position Jamaica as the next global ‘investment destination of choice’, and is part of a five-year development project, in partnership with the Inter-American Development Bank (IDB), to expand the country’s Global Services Sector (GSS).
The event will highlight various innovative, mutually beneficial, and sustainable sector-based investment opportunities to potential investors from all over the world, particularly in the areas of Agribusiness, Global Digital Services, Logistics/Special Economic Zones, Manufacturing, Finance and Tourism.
Global Business Paired with Local Sustainability
The continued improvement of Jamaica’s economy will encourage a new wave of collaborative and multi-faceted investment in Jamaica which uniquely prioritizes sustainable projects deemed to be in both the national and global interest.
To assist with this bridging of the evolving needs of international investors and the local social development needs in Jamaica itself, a variety of both public and private sector initiatives are being rolled out ‘on the ground’ in the country. These initiatives include the National Investment Policy, Global Services Sector Project and the Business Environment Reforms Agenda. Importantly, these initiatives will give Jamaicans new career development opportunities and further strengthen the local economy, whilst enabling high-value skills development and offering an unprecedented level of support to investors.
The Holistic and Ethical Choice
Specifically, for the Global Service Sector (GSS) Project, the skills training and apprenticeship programmes will develop the Jamaican population in higher value-added service capabilities such as Management and Leadership, IT Infrastructure, Communication, Digital Marketing, Software Development and Integration, Critical and Analytical thinking, and human-centred Interaction Design.
Impressively, under the Apprenticeship Programme, close to 3,000 Jamaicans will be trained by the end of the GSS project, while under the High School Immersion Programme, 20,000 local students will be trained in enhanced job readiness and specialized tracks, creating monumental benefits for both Jamaica and its investors.
This type of thought-leading holistic and ethical approach to global business is transforming perceptions of global investment, and Jamaica is leading the charge.
Choose Jamaica. Invest in Jamaica.
More Information:
ABOUT JAMPRO
The Jamaica Promotions Corporation (JAMPRO)’s mission is to drive economic development through growth in investment and export. JAMPRO is an Agency of the Ministry of Industry, Investment, and Commerce. For more information on JAMPRO, please visit https://dobusinessjamaica.com/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221124005264/en/
Contact information
Amy Goulding
G&A Communications Inc
Tel: +1 246 820 8695
E-mail: amy@gacaribbean.com
JAMPRO
Jamaica Promotions Corporation
Marketing Communications
marketing@jamprocorp.com
(876) 978-7755
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brenus Pharma Presented New Preclinical and Early Clinical Data in Colorectal Cancer During AACR Immuno-Oncology Conference 202619.2.2026 09:50:00 EET | Press release
Brenus Pharma, a clinical-stage biotechnology company pioneering in vivo “off-the-shelf” immunotherapies, announced the selection of an abstract for a poster presentation at the American Association for Cancer Research Immuno-Oncology (AACRIO) annual conference (February 18-21, 2026), in Los Angeles. The poster showcases new preclinical data and early clinical insights from the company's lead candidate, STC-1010, supporting it as a promising therapeutic option for MSS, immune-cold colorectal cancer (CRC)—a major unmet clinical need. In a syngeneic CT26 model, murine STC-1010 significantly inhibits tumor growth and extends survival by 40%. New mechanistic datas reveal expansion of CD4⁺ and CD8⁺ T cells in draining lymph nodes alongside a significant humoral response compared to control, demonstrating coordinated cellular and humoral immune activation in vivo. Other findings show that dendritic cells efficiently capture STC-1010, leading to their activation as demonstrated by transcripto
ENHERTU ® Type II Variation Application Validated in the EU as Post-Neoadjuvant Treatment for Patients with HER2 Positive Early Breast Cancer19.2.2026 09:30:00 EET | Press release
The European Medicines Agency (EMA) has validated the Type II Variation marketing authorization application for ENHERTU® (trastuzumab deruxtecan) as a monotherapy for adult patients with HER2 positive (immunohistochemistry [IHC] 3+ or in-situ hybridization [ISH]+) breast cancer who have residual invasive disease after neoadjuvant HER2 targeted treatment. ENHERTU is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The validation confirms the completion of the application and commences the scientific review process by the EMA’s Committee for Medicinal Products for Human Use (CHMP). The application is based on data from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. In the trial, ENHERTU demo
NHOA Energy Advances Delivery of the 51 MWh Broni Battery for Neoen in Italy19.2.2026 09:00:00 EET | Press release
NHOA Energy, global provider of utility-scale energy storage systems, is advancing the construction of the Broni Battery, a 10 MW/51 MWh project located in Broni (Pavia), Italy, executed for Neoen, one of the world’s leading independent producers of renewable energy. Civil works at the site are currently underway and advancing on schedule, with commissioning activities planned to start in late spring 2026. Once operational, the Broni Battery will provide essential flexibility services to the Italian electricity system, supporting grid stability and reliability as renewable energy penetration continues to increase. The project represents Neoen’s first battery storage asset in Italy and marks a strategic step in the company’s expansion, as it continues to grow its battery storage portfolio in key markets worldwide to support power system flexibility. The Broni Battery further strengthens NHOA Energy’s long-term commitment to the Italian market, where the company has deep industrial roots
Compass Pathways Announces Pricing of $150 Million Public Offering19.2.2026 03:18:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, announced today the pricing of its public offering of 17,500,000 American Depositary Shares (“ADSs”) at a public offering price of $8.00 per ADS, each representing one ordinary share, and in lieu of ADSs, to certain institutional investors, pre-funded warrants to purchase up to 1,250,000 ADSs at a public offering price of $7.9999 per pre-funded warrant. In addition, Compass Pathways has granted the underwriters a 30-day option to purchase up to an additional 2,812,500 ADSs at the public offering price, less the underwriting discounts and commissions. All of the securities are to be sold by Compass Pathways. The offering is expected to close on or about February 20, 2026, subject to the satisfaction of customary closing conditions. The gross proceeds to Compass Pathways from the offering, before deducting underwriting discounts and commissions and other est
Perpetual Atomics Ltd, QSA Europe, QSA Global and Reef Origin to Collaborate on Building Radioisotope Power Systems in Europe18.2.2026 17:44:00 EET | Press release
Perpetual Atomics Ltd, QSA Europe (a trading name of Loma Systems s.r.o.), QSA Global, Inc., and Reef Origin signed an MOU in Prague to collaborate on the industrialized production of radioisotope power systems in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260218036211/en/ Teams from Perpetual Atomics & QSA Global (USA and Czechia) at the facilities in Czechia This MOU builds on the existing collaboration between QSA Global, Inc. and Perpetual Atomics Ltd by expanding and strengthening the capacity and capability to produce radioisotope power systems in Europe. The key partnership with QSA Europe provides access to existing facilities, capabilities, knowledge, and know-how for the storage, handling, and distribution of commercial radioisotope systems for terrestrial applications. This capability is directly transferable to radioisotope power technologies for space. Radioisotope and nuclear power technologies are
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom